Ionis Pharmaceuticals INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Ionis Pharmaceuticals, a leader in RNA-targeted medicines, reported significant revenue growth in 2025 driven by new product launches and a robust pipeline, despite a net loss.
NASDAQ
10-K: Ionis Pharmaceuticals Reports 2024 Results, Highlights Commercial Progress and Pipeline Advancements
Ionis Pharmaceuticals reports $705 million in revenue for 2024, marking a year of commercial expansion and pipeline progress.
NASDAQ
10-K: Ionis Pharmaceuticals Reports Progress in RNA-Targeted Therapies and Financial Strength in 2023
Ionis Pharmaceuticals highlights advancements in RNA-targeted medicines, FDA approvals, and a strong financial position with $2.3 billion in cash reserves at the end of 2023.